Phytopharma's Zemaphyte Reduces Severe Atopic Eczema

16 June 1996

- UK firm Phytopharma's Zemaphyte has achieved "highly significant" reductions in symptoms in severely-affected atopic eczema patients, according to interim results of a Phase III trial. Zemaphyte, an extract of plants used in traditional Chinese medicine, reduced the number of lesions with no unexpected side effects. The firm says the study should be concluded later this year, and plans to file for approval in the UK shortly. Once approved, Zemaphyte will be marketed in Europe by Rhone-Poulenc Rorer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight